


DELIVERED BY HAND ON DECEMBER 16, 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Pramod SRIVASTAVA
Application No.: 09/090,754
Filed: June 4, 1998



Group Art Unit: 1642
Examiner: G. Bansal

For: COMPOSITIONS AND METHODS
FOR THE PREVENTION AND
TREATMENT OF PRIMARY AND
METASTATIC NEOPLASTIC
DISEASES AND INFECTIOUS
DISEASES WITH HEAT
SHOCK/STRESS PROTEINS

Atty. Dkt. No.: 8449-041

RECEIVED

DEC 18 1998 P#2

MATRIX DOCUMENT SERVICE CENTER
230/198

RECEIVED

DEC 10 1998

GROUP 1700

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 AND 1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each person associated with the filing and prosecution of the instant application which are or may be material to the patentability of any claim of the instant application, attorneys for Applicant hereby direct the Examiner's attention to references AA-FJ listed on the four attached Lists of References Cited by Applicant.

The instant application is a divisional of co-pending Application No. 08/527,391 filed on September 13, 1995, which issued as U.S. Patent No. 5,837,251 on November 17, 1998, to which the instant application claims priority under 35 U.S.C. § 120.

Copies of references AA-DC, listed on the first List of References Cited by Applicant submitted herewith, were submitted with an Information Disclosure Statement filed on June 12, 1996 in connection with prior Application No. 08/527,391.

Copies of references DD-DY, listed on the second List of References Cited by Applicant submitted herewith, were submitted with a Supplemental Information Disclosure Statement filed on March 4, 1997 in connection with prior application 08/527,391.

Copies of references DZ-ED, listed on the third List of References Cited by Applicant submitted herewith, were submitted with a Second Supplemental Information Disclosure Statement filed on December 9, 1997 in connection with prior application 08/527,391.

In accordance with the provisions of 37 C.F.R. § 1.98(d), and so as not to overburden the Patent Office files, no copies of references AA-ED are included herewith. Applicant respectfully refers the Examiner to the file of the prior application 08/527,391 for copies of these references. However, Applicant will submit copies of the aforementioned references upon request by the Examiner.

A fourth List of References Cited by Applicant, submitted herewith, lists references EE-FJ. Copies of references EE-EH and FH-FJ are also submitted herewith. Pursuant to 37 C.F.R. § 1.98(a)(2)(iii), copies of references EI-FG, which are pending U.S. patent applications, are not enclosed. Applicant notes that reference FI is a Written Opinion, dated July 1, 1997, issued in connection with Patent Cooperation Treaty (PCT) Application No. PCT/US96/14557, which is a foreign counterpart of prior Application No. 08/527,391.

While not to be construed that the Examiner should not review and consider all of the listed references, the Examiner's attention is particularly directed to the following references: Welch et al., 1995, Mol. Cell. Biol. 5: 1229-1237 (CZ); U.S. Patent No. 5,747,332 (EE); International Publication No. WO 98/12208 (FH); Written Opinion dated July 1, 1997, Related PCT Application No. PCT/US96/14557 (FI); Sadis and Hightower, 1992, Biochemistry 31: 9406-9412 (FJ).

Identification of references AA-FJ is not to be construed an admission of Applicant or attorneys for Applicant that such references are available as "prior art" against the instant application.

Applicant respectfully requests that the Examiner review references AA-FJ and that these references be made of record in the file history of the instant application.

Applicant believes this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. Accordingly, no fee is believed to be required for this submission, in accordance with the provisions of 37 C.F.R. § 1.97(b)(3). However, should a fee be required, please charge the required amount to Pennie & Edmonds LLP deposit account no. 16-1150.

Respectfully submitted,

Date: December 16, 1998

 S. Leslie Misrock 18,872
S. Leslie Misrock (Reg. No.)

By:  Jonathan L. Klein

41,119
(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10109
(212) 790-9090